Table 6 Clinical HHT-related features of the 9 patients with hereditary hemorrhagic telangiectasia (HHT) with ascertained SarsCov-2 infection

Clinical, HHT-related (n = 9^a)

Epistaxis, n (%)

9 (100)

Visceral AVMs, n (%)

2 (22.2)

Epistaxis Worsening, n (%)

3 (33.3)

Epistaxis Unchanged, n (%)

6 (66.7)

Epistaxis Improvement, n (%)

0

Increased bleeding from oral telangiectases, n (%)

0

Chronic Anemia

Hb deficit level (n = 6^a)

 Mild, n

5

 Intermediate, n

1

 Severe, n

0

 Very Severe, n

0

Iron replacement therapy (n = 8^a)

 Oral Supplementation, n

3

 IV Injection, n

2

 Blood Transfusion, n

0